Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Schenefeld, Germany, 22869
- proDERM
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diffuse hair loss
- Modified Savin Score I to III
- Hair length of at least 2 cm
Exclusion Criteria:
- Pathological hair loss (like alopecia areata, universalis or totalis; scarring alopecias; androgenic alopecia; inflammatory conditions of the scalp)
- Symptomatic diffuse alopecia due to pathological low iron concentration or thyroid gland disorder
- Acute telogen effluvium
- Recent or concomitant treatment with any drugs that may cause hair loss
- Concomitant diseases that can cause hair loss
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pantovigar vegan treatment
|
Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Self-assessment questionnaire for product acceptance by subjects
Time Frame: Months 3
|
Months 3
|
|
Self-assessment questionnaire for product acceptance by subjects
Time Frame: Months 6
|
Months 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Effect on hair growth assessed by phototrichogram analysis
Time Frame: Baseline up to month 6
|
Baseline up to month 6
|
|
Change from baseline of blood parameters: Ferritin
Time Frame: Baseline up to month 6
|
Baseline up to month 6
|
|
Change from baseline of several blood parameters: Vitamin B1
Time Frame: Baseline up to month 6
|
Baseline up to month 6
|
|
Change from baseline of several blood parameters: Biotin
Time Frame: Baseline up to month 6
|
Baseline up to month 6
|
|
Change from baseline of several blood parameters: Folic acid
Time Frame: Baseline up to month 6
|
Baseline up to month 6
|
|
Change from baseline of several blood parameters: Hematocrit
Time Frame: Baseline up to month 6
|
Baseline up to month 6
|
|
Change from baseline of several blood parameters: Pantothenic Acid
Time Frame: Baseline up to months 6
|
Baseline up to months 6
|
|
Occurrence of treatment-emergent adverse reactions and treatment-emergent serious adverse reactions
Time Frame: Baseline up to months 6
|
Baseline up to months 6
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Merz Medical Expert, Merz Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M900411001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.